Metabolomics And Lipidomics Analyses By 1h Nuclear Magnetic Resonance Of Schizophrenia Patient Serum Reveal Potential Peripheral Biomarkers For Diagnosis

dc.creatorTasic L.
dc.creatorPontes J.G.M.
dc.creatorCarvalho M.S.
dc.creatorCruz G.
dc.creatorDal Mas C.
dc.creatorSethi S.
dc.creatorPedrini M.
dc.creatorRizzo L.B.
dc.creatorZeni-Graiff M.
dc.creatorAsevedo E.
dc.creatorLacerda A.L.T.
dc.creatorBressan R.A.
dc.creatorPoppi R.J.
dc.creatorBrietzke E.
dc.creatorHayashi M.A.F.
dc.date2016
dc.date2017-08-17T19:11:01Z
dc.date2017-08-17T19:11:01Z
dc.date.accessioned2018-03-29T05:15:57Z
dc.date.available2018-03-29T05:15:57Z
dc.identifierSchizophrenia Research. Elsevier B.v., v. 185, p. 182 - 189, 2016.
dc.identifier0920-9964
dc.identifier10.1016/j.schres.2016.12.024
dc.identifierhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85009518375&doi=10.1016%2fj.schres.2016.12.024&partnerID=40&md5=9051ea3abf79ab450be28ec6d4528a85
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/323172
dc.identifier2-s2.0-85009518375
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1357335
dc.descriptionUsing 1H NMR-based metabolomics in association to chemometrics analysis, we analyzed here the metabolic differences between schizophrenia patients (SCZ) compared to healthy controls (HCs). HCs and SCZ patients underwent clinical interview using the Structured Clinical Interview for DSM Disorders (SCID). SCZ patients were further assessed by Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale, Global Assessment of Functioning Scale (GAF), and Clinical Global Impressions Scale (CGI). Using the principal component analysis (PCA) and supervised partial least-squares discriminate analysis (PLS-DA) in obtained NMR data, a clear group separation between HCs and SCZ patients was achieved. Interestingly, all metabolite compounds identified as exclusively present in the SCZ group, except for the gamma-aminobutyric acid (GABA), were never previously associated with mental disorders. Although the initial perception of an absence of obvious biological link among the different key molecules exclusively observed in each group, and no identification of any specific pathway yet, the present work represents an important contribution for the identification of potential biomarkers to inform diagnosis, as it was possible to completely separate the affected SCZ patients from HCs, with no outliers or exceptions. In addition, the data presented here reinforced the role of the modulation of glycolysis pathway and the loss of GABA interneuron/hyperglutamate hypothesis in SCZ. © 2016.
dc.description185
dc.description182
dc.description189
dc.languageEnglish
dc.publisherElsevier B.V.
dc.relationSchizophrenia Research
dc.rightsfechado
dc.sourceScopus
dc.subjectBiomarkers
dc.subjectLipidomics
dc.subjectMetabolomics
dc.subjectNmr
dc.subjectPsychosis
dc.subjectSchizophrenia
dc.subjectSerum
dc.titleMetabolomics And Lipidomics Analyses By 1h Nuclear Magnetic Resonance Of Schizophrenia Patient Serum Reveal Potential Peripheral Biomarkers For Diagnosis
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución